Microalbuminuria in systolic and diastolic chronic heart failure patients by Orea-Tejeda, Arturo et al.
ORIGINAL ARTICLE
Cardiology Journal
2008, Vol. 15, No. 2, pp. 143–149
Copyright © 2008 Via Medica
ISSN 1897–5593
www.cardiologyjournal.org 143
Address for correspondence: MSc Lilia Castillo-Martínez, Providencia 1218–A 402 Col. del Valle, Benito Juárez, CP 03100
Mexico City, Mexico, tel./fax: (5255) 55 13 93 84, e-mail: caml1225@yahoo.com
Received: 28.12.2007 Accepted: 13.02.2008
Microalbuminuria in systolic and diastolic
chronic heart failure patients
Arturo Orea-Tejeda1, 2, Eloisa Colín-Ramírez1, 2, Thierry Hernández-Gilsoul1,
Lilia Castillo-Martínez1, 2, Marcela Abasta-Jiménez3, Enrique Asensio-Lafuente2,
René Narváez David2 and Joel Dorantes-García2
1Heart Failure Clinic Instituto Nacional de Ciencias Médicas y Nutrición
“Salvador Zubirán”, Mexico City, México
2Cardiology Department Instituto Nacional de Ciencias Médicas y Nutrición
“Salvador Zubirán”, Mexico City, México
3Nephrology Department Instituto Nacional de Ciencias Médicas y Nutrición
“Salvador Zubirán”, Mexico City, México
Abstract
Background: Microalbuminuria is considered a major risk factor predisposing to cardiovas-
cular morbidity and mortality. Microalbuminuria levels in patients with or without diabetes
have been associated with a higher risk of chronic heart failure (HF). However, there are
limited data regarding prevalence of microalbuminuria in chronic heart failure and its prog-
nostic value. The aim of this study was to assess the occurence of microalbuminuria in chronic
heart failure patients as well as its association with clinical, echocardiographic, and body
composition markers.
Methods: In a cross-sectional study, we included 72 chronic heart failure patients (NYHA I–III)
on standard HF therapy. All patients had an echocardiogram and body composition by vector
bioelectric impedance analysis (measured by Body Stat Quad Scan).
Results: The studied population consisted of 64% men at mean age of 62.6 ± 15.1 years.
Patients were divided into systolic and diastolic HF groups. Microalbuminuria was observed
in 40% of diastolic and 24% systolic HF patients (p = 0.04). Microalbuminuria was present
in more patients with volume overload (80 vs. 21.9%, p = 0.002), with a worse phase angle and
lower serum albumin (4.7 vs. 5.9° and 3.5 vs. 4.0 mg/dl, p = 0.02) and higher pulmonary
arterial pressure compared with patients without microalbuminuria in systolic HF patients.
There was no significant association between frequency of microalbuminuria and ejection
fraction. In the diastolic HF group, the presence of microalbuminuria was not associated with
any known risk factor.
Conclusions: Microalbuminuria was more frequent in diastolic than systolic HF patients. In
systolic HF patients microalbuminuria was associated with factors known to be markers of
worse prognosis. (Cardiol J 2008; 15: 143–149)
Key words: microalbuminuria, systolic and diastolic heart failure, body
composition markers
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Introduction
Microalbuminuria has been recognized as a risk
factor for cardiovascular disease (CVD) [1, 2], espe-
cially in coronary heart disease (CHD) [3–5], and it
occurs most often in hypertensive and diabetic pa-
tients. Moreover, microalbuminuria has been pro-
posed as a useful parameter in patients at high risk
of developing heart failure (HF) [6]. In patients with
diabetes mellitus older than 50 years, 4% with al-
buminuria > 20 mg/L developed HF [7]. In addi-
tion, the HOPE study showed that the rate of de-
veloping HF significantly increased in the presen-
ce of microalbuminuria (1.82) [8]. In spite of this
information, its role in the development of HF has
not yet been established [9–14].
Microalbuminuria is not only associated with
high risk for CVD diseases: a cross-sectional study
of 94 stable chronic heart failure patients found that
32% of them had microalbuminuria and no signifi-
cant reduction of glomerular filtration rate [15].
It has also been associated with elevated levels of
several inflammatory factors in the presence or
absence of hypertension or diabetes. The associa-
tion of inflammatory factors with microalbuminuria
also was present regardless of the presence or ab-
sence of CVD [16].
Since microalbuminuria has been associated
with several HF risk factors, the aim of this study
was to asses the prevalence of microalbuminuria in
systolic and diastolic chronic heart failure patients
in relation to clinical, echocardiographic and body
composition markers.
Methods
We carried out a cross-sectional study that in-
cluded 72 patients with chronic heart failure (CHF).
Among them, 42 had systolic HF and 30 had dia-
stolic HF. They were consecutively included from
January 2004 to April 2006. They were stable out-
patients in New York Heart Association (NYHA)
functional classes I–III, attending the Heart Failure
Clinic at the Instituto Nacional de Ciencias Médicas
y Nutrición Salvador Zubirán (INCMNSZ). Patients
were recruited if they were ≥ 18 years old, with
confirmed heart failure diagnosis (defined as systo-
lic and/or diastolic dysfunction by an echocardio-
gram; and if showing signs and symptoms of heart
failure). Subjects were excluded if they had prote-
inuria and end-stage renal disease, non-controlled
disthyroidism, hepatic failure, valvular disease,
chronic obstructive pulmonary disease, pericardial
constriction, restrictive miocardiopathies, unstable
ischemic heart disease (unstable angina and/or acute
myocardial infarction), recent myocardial revascu-
larization procedures (percutaneous transluminal
coronary artery angioplasty and/or aortic-coronary
bypass grafting in the last three months) or life thre-
atening arrhythmias.
All patients were on standard HF therapy (diu-
retics, ACE inhibitors, angiotensin II antagonists,
aldosterone receptor blockers, digitalis and beta-
adreno-receptor blockers). No patients were under-
going insulin treatment. Diabetic patients were on
oral hypoglicemiant drugs
Systolic ventricular dysfunction was diagnosed
when the left ventricle ejection fraction (LVEF) was
£ 45% and/or shortening fraction was £ 28%, and
severe left ventricle wall movement abnormalities
or dilatation of the left ventricle (end diastolic left
ventricular diameter ≥ 55 mm) were present. Dia-
stolic dysfunction was diagnosed when the LVEF
was > 45%, and shortening fraction ≥ 28%, witho-
ut severe segmental left ventricle wall movement
abnormalities but there was an abnormal left ven-
tricular filling and relaxation patterns (in cases wi-
thout atrial fibrillation in which of them was not
possible to get Doppler inflow mitral pattern) and
evidence of left ventricular hypertrophy ((posterior
wall + interventricular septum thickness)/2 ≥ 1.3 cm),
posterior wall thickness ≥ 1.2 cm, and/or left atrial
dilatation ≥ 4.5 cm were present. Diastolic and/or
systolic dysfunction was diagnosed when one or
more of the above points were observed in the echo-
cardiogram [17, 18].
The study was approved by the local bioethi-
cal committee and all patients gave their informed
consent.
Body composition evaluation
Anthropometry. Weight and height were me-
asured in accordance to the reference manual of
anthropometric standardization [19]: all subjects
wore light clothing and were barefoot. Body mass
index (BMI) was calculated by dividing total body
weight [kg] by the squared height (in square metres).
Bioelectrical impedance analysis. Whole-
-body bioelectrical impedance was measured by
using tetrapolar and multiple frequency equip-
ment BodyStat QuadScan 4000 (BODYSTAT
LTD; Isle of Man, British Isles). All measure-
ments were made by the same investigator follo-
wing the method reported in the literature [20].
The standard 50 kHz frequency was selected to
obtain total body water (TBW), extra cellular
water (ECW), resistance (R), reactance (Xc) and
phase angle for all patients. The resistance and
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reactance values were normalized by the height
(H) of the subjects, thus expressing both R/H and
Xc/H in Ohm/m and were plotted in the RXc graph
(abscise R/H, ordinate Xc/H) [21].
Biochemical analysis
Twenty-four-hour urine samples were collec-
ted in standardized conditions for albumin quantifi-
cation. The urinary albumin concentration was
measured by ELISA technique, and urinary albumin
excretion was calculated as urinary albumin concen-
tration multiplied by diuresis. Serum creatinine was
measured using standard techniques. Serum creati-
nine, age, weight and gender were used to calcula-
te glomerular filtration rate using the Cockcroft-
-Gault equation (GFRc) [22].
Microalbuminuria was defined as 20 to 200 µg/min
albumin excreted by urine per minute (15 to
150 µg/min in urine samples collected at night) [23].
Statistical analysis
Continuous variables are given as mean ± stan-
dard deviation (SD), and categorical variables are
presented as absolute and relative frequency. Com-
parisons among groups were made with Pearson’s
c2 for categorical variables and unpaired t-test for
continuous variables. A p value < 0.05 was consi-
dered statistically significant. Analyses were per-
formed using a commercially available package
(SPSS for Windows, version 10.0 1999 Chicago
SPSS Inc.).
Results
Seventy-two patients with CHF were included,
64.3% were men, 63.9% had hypertension and
52.8% had diabetes mellitus type 2. Microalbumi-
nuria was present in 30.6% of all patients, and in
systolic HF patients the prevalence was significan-
tly lower compared with diastolic HF patients (23.8
vs. 40%, respectively; p = 0.04).
Among systolic and diastolic HF patients, we
did not find statistically significant differences in
NYHA functional class. Nevertheless, those with
diastolic HF had higher BMI (32.4 ± 8.6 vs. 24.9 ±
± 5.7; p 0.001), volume overload [body impendance
vector analysis (BIVA) 75.0% vs. 80%; p = 0.013)]
and oedema (58.3 vs. 30%; p = 0.001), and less al-
bumin serum level (3.4 ± 0.1 vs. 3.5 ± 0.2; p =
= 0.025) compared with systolic HF patients.
Table 1 shows the comparison between pa-
tients with and without microalbuminuria in systo-
lic HF, and we can observed that those with micro-
albuminuria had a higher prevalence of type 2 dia-
betes and more volume overload, as well as incre-
ased frequency of high systolic pulmonary artery
pressure, than patients without microalbuminuria.
These patients also had lower phase angle and al-
bumin levels, even after adjustments for diabetes
presence. No significant association was found with
NYHA functional classification or ejection fraction.
In the diastolic heart failure group, microalbumi-
nuria was not associated with any variable (Table 2).
Fewer patients with systolic heart failure and
microalbuminuria were receiving angiotensin re-
ceptor blockers than those without microalbuminu-
ria; on the contrary, those with diastolic HF and
microalbuminuria did not show such an apparent
benefit that could elicit a sort of paradoxical effect
of angiotensin receptor blockers (ARBs) (Table 3).
Table 4 shows the multivariate analysis, where
only volume overload by BIVA was independently
associated with the presence of microalbuminuria
after adjustments for ejection fraction and diabetes.
Discussion
The main finding of this study was the relation
between volume overload by BIVA and the presen-
ce of microalbuminuria in patients with systolic dys-
function, but not in those with diastolic dysfunction.
In our population, microalbuminuria was found
in 30.6%; however, in those with diastolic heart fa-
ilure it was 40.6%, even though most of them were
receiving treatment with angiotensin-converting
enzyme inhibitors (ACEI) or ARBs that, according
to available information, reduce microalbuminuria [24].
Nevertheless, significantly fewer patients with sy-
stolic HF and microalbuminuria were receiving
ARBs than those with diastolic HF and microalbu-
minuria, so the latter did not show such an apparent
benefit derived from therapy. Such a finding could
be related to a sort of paradoxical effect of ARBs.
The prevalence of microalbuminuria in hyper-
tensive and diabetic patients (10–15% and 15–20%,
respectively) is increased compared with the gene-
ral population (6–8%) [25, 26]. However, in heart
failure patients it was not recorded until the study
of Van de Wal, who found it in one third of his pa-
tients. Such a prevalence is higher than in diabetic
and hypertensive patients [15, 27, 28].
Several pathophysiological mechanisms have
been involved. Microalbuminuria has traditionally
been thought of as an expression of renal damage
because of increased glomerular blood flow and in-
creased hydraulic pressure that leads to hyperfil-
tration and excretion of protein [29]. However, in
our cases we did not find significant differences
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among patients with microalbuminuria in creatini-
ne serum levels and glomerular filtration rates
(GFRc), with respect to those without it.
Microalbuminuria has also been considered as
a manifestation of generalized endothelial dysfunction,
which results in leakage of albumin through the
endothelium and glomerular basement membrane,
probably in the context of the severe abnormality
of endothelial function observed in HF. These con-
ditions explain its higher prevalence in HF patients
[15, 30, 31].
Other studies have demonstrated increased
urinary albumin excretion, attributed in some way
to cardiac systolic dysfunction, as a reflection of
extensive endothelial and vascular changes [32, 33].
Van de Wal et al. [15], however, rejected this
Table 1. Characteristics of patients with systolic dysfunction according to the presence or absence of
microalbuminuria.
Microalbuminuria (n = 10) No microalbuminuria (n = 32)
Males 70.0% (7) 62.5% (20)
Age (years) 67.7 ± 15.23 62.16 ± 15.09
Body mass index [kg/m2] 24.9 ± 5.7 26.9 ± 4.2
Weight [kg] 63.6 ± 20.1 66.8 ± 15.5
Height [cm] 160.3 ± 13.2 154.5 ± 16.0
Extra cellular water (%) 24.6 ± 0.8 23.6 ± 0.4
Patients with volume overload BIVA  80.0% (8) 21.9% (7)*
Phase angle (°) 4.7 ± 0.4 5.9 ± 0.2*
Albumin [g/dL] 3.5 ± 0.2 4.0 ± 0.7*
Total cholesterol [mg/dL] 157.0 ± 21.1 183.2 ± 7.7
LDL cholesterol [mg/dL] 92.0 ± 11.3 104.7 ± 24.8
HDL cholesterol [mg/dL] 41.5 ± 19.1 37.1 ± 6.5
Triacylglycerol [mg/dL] 112.5 ± 20.5 234.6 ± 157.6
Sodium [mmol/dL] 135.6 ± 2.8 137.9 ± 2.7
Glucose [mg/dL] 200.4 ± 109 110.1 ± 38
Serum creatinine [mg/dL] 1.18 ± 0.23 1.04 ± 0.29
GFRc [mL/min] 52.0 ± 17.85 72.0 ± 29.9
LVSF (%) 16.8 ± 3.8 24.9 ± 8.8
LVEF (%) 30.0 ± 9.6 40.0 ± 14.7
LVEDd [mm] 54.1 ± 10.7 52.1 ± 9.7
LVESd [mm] 43.3 ± 10.4 39.3 ± 11.5
IVS [mm] 11.3 ± 3.3 10.2 ± 1.9
PW [mm] 10.8 ± 3.0 9.3 ± 1.4
LAD [mm] 43.3 ± 8.1 44.5 ± 7.9
Ao D [mm] 33.2 ± 2.6 31.4 ± 6.2
RVDd [mm] 34.0 ± 9.7 9.3 ± 1.4
IVRTI (seg) 65.9 ± 16.8 115.9 ± 9.0*
PAP [mm Hg] 79.9 ± 5.5 49.0 ± 2.25*
NYHA I 60.0% (6) 68.7% (22)
NYHA II 30.0% (3) 25% (8)
NYHA III 10.0% (1) 6.3% (2)
Oedema 30.0% (3) 12.5% (4)
Ischemic etiology 70.0% (7) 65.6% (21)
Dyslipidemia 80.0% (8) 90.6% (29)
Hypertension 50.0% (5) 53.1% (17)
Diabetes mellitus 90.0% (9) 40.6% (13)*
BIVA — body impedance vector analysis; LVSF — left ventricular shortening fraction, LVEF — left ventricular ejection fraction; LVEDd — left ventricular
end diastolic diameter; LVESd — left ventricular end systolic diameter; IVS — interventricular septum, PW — posterior wall; LAD — left atrium diameter;
Ao D — aorta diameter; RVDd — right ventricular diastolic diameter; IVRTI — isovolumetric relaxation time index; PAP — pulmonary artery
pressure; GFRc — glomerular filtration rate. Values are expressed as mean ± standard deviation or percentage when corresponding; *p < 0.05
compared to microalbuminuria
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explanation because their patients had no differen-
ces in left ventricular ejection fractions or in other
markers of systolic function.
In our cases, the prevalence of microalbumi-
nuria has also shown differences regarding the
type of HF; it was more frequent in those with
diastolic HF. This finding is in agreement with
Van de Wal et al. [15] because in those cases with
diastolic dysfunction and preserved systolic func-
tion, microalbuminuria was present, although this
group received ACEI or ARB. However, in those
patients with systolic heart failure, microalbumi-
nuria was associated with more volume overload
and lesser phase angle in the electrical bioimpe-
dance study as an expression of increased total
extracellular water, as well as severe pulmonary
Table 2. Characteristics of patients with diastolic dysfunction according to the presence or absence of
microalbuminuria.
Microalbuminuria (n = 12) No microalbuminuria (n = 18)
Males 50.0% (6) 38.9% (7)
Age (years) 61.8 ± 15.4 64.9 ± 18.8
Body mass index [kg/m2] 32.4 ± 8.6 32.3 ± 8.3
Weight [kg] 82.8 ± 25.4 77.6 ± 22.7
Height (cm) 159.6 ± 12.4 154.9 ± 9.1
Extra cellular water (%) 22.5 ± 1.5 22.3 ± 3.7
Patients with volume overload BIVA  75.0% (9)  55.6% (10)
Phase angle (°) 5.7 ± 1.9 5.04 ± 1.1
Albumin [g/dL] 3.4 ± 0.1 3.8 ± 0.2
Total cholesterol [mg/dL] 163.8 ± 25.0 185.9 ± 36.0
LDL cholesterol [mg/dL] 92.1 ± 13.0 130.5 ± 10.6
HDL cholesterol [mg/dL] 34.0 ± 10.1 41.7 ± 6.6
Triacylglycerol [mg/dL] 158.4 ± 20.5 131.3 ± 46.2
Sodium [mmol/dL] 138.8 ± 2.1 136.9 ± 3.6
Glucose [mg/dL] 136.6 ± 35.7 117.1 ± 55.0
Serum creatinine [mg/dL] 1.07 ± 0.33 0.99 ± 0.29
GFRc [mL/min] 66.09 ± 17.33 78.75 ± 31.8
LVSF (%) 36.0 ± 12.7 36.2 ± 7.9
LVEF (%) 54.5 ± 16.0 58.5 ± 8.8
LVEDd [mm] 48.9 ± 8.7 44.8 ± 6.8
LVESd [mm] 31.4 ± 11.7 28.4 ± 6.8
IVS [mm] 14.4 ± 1.6 13.4 ± 2.6
PW [mm] 12.3 ± 1.3 11.9 ± 2.1
LAD [mm] 44.3 ± 6.6 45.9 ± 4.6
Ao D [mm] 31.4 ± 3.7 29.2 ± 3.0
RVDd [mm] 27.0 ± 0.6 58.5 ± 0.6
IVRTI [seg] 97.5 ± 10.4 109.4 ± 21.0
PAP [mm Hg] 59.7 ± 18.1 56.6 ± 19.0
NYHA I 33.3% (4) 66.7% (12)
NYHA II 58.3% (7) 16.7% (3)
NYHA III 8.3% (1) 16.7% (3)
Oedema 58.3% (7) 50.0% (9)
Ischemic etiology 41.7% (5) 33.3% (6)
Dyslipidemia 58.3% (7) 100% (18)*
Hypertension 83.3% (10) 77.8% (14)
Diabetes mellitus 75.0% (9) 38.9% (7)
BIVA — body impedance vector analysis; LVSF — left ventricular shortening fraction; LVEF — left ventricular ejection fraction; LVEDd — left ventricular
end diastolic diameter; LVESd — left ventricular end systolic diameter; IVS — interventricular septum; PW — posterior wall; LAD — left atrium diameter;
Ao D — aorta diameter; RVDd — right ventricular diastolic diameter; IVRTI — isovolumetric relaxation time index; PAP — pulmonary artery pressure;
GFRc — glomerular filtration rate. Values are expressed as mean ± standard deviation or percentage when corresponding; *p < 0.05 compared
to microalbuminuria
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hypertension compared with patients without
albuminuria, even if all these patients also received
ACEI. Therefore, it is possible that in these pa-
tients, the renin angiotensine system could be
more active [15].
In another way, the fact that systolic HF pa-
tients were associated with worse parameters of
BIVA, higher PAP and lower BMI, allows us to spe-
culate whether these characteristics indicate the
early stages of cardiac cachexia , which, in other
papers, have been found to be related to elevated
levels of TNF-a [34]. However, in our cases it was
not investigated.
Nonetheless, diastolic and systolic HF patients
have no differences in NYHA functional class. Ho-
wever, in systolic HF microalbuminuria presence
could be an easily available parameter of more se-
vere cardiovascular damage and advanced stage of
cardiac dysfunction.
Limitations of the study
Being an observational study, no determina-
tion of neurohormonal or NT-proBNP concentra-
tion was performed. In addition, we could not in-
fer the prognostic impact of microalbuminuria, as
is suggested by its association with other bad pro-
gnosis factors. TNF-a levels were not determi-
ned and their potential roll in the cardiovascular
damage and microalbuminuria presence remain
unknown.
Conclusions
In summary, microalbuminuria was more fre-
quent in diastolic than systolic HF patients.  In sy-
stolic HF patients, microalbuminuria was associa-
ted with factors known to be markers of worse pro-
gnosis. More information is necessary before
drawing any conclusions regarding the presence
Table 3. Medication in patients with systolic and diastolic dysfunction according to the presence or
absence of microalbuminuria.
Drug Microalbuminuria No microalbuminuria
Systolic heart failure patients (n = 10) (n = 32)
Beta-adrenoreceptor antagonist 90.0% (9) 90.6% (29)
ACE inhibitor 90.0% (9) 65.6% (21)
Angiotensin receptor blockers 10.0% (1) 53.1% (17)*
Thiazide diuretics 50.0% (5) 53.1% (17)
Loop diuretics 40.0% (4) 12.5% (4)
Digitalis 50.0% (5) 53.1% (17)
Oral nitrate 10.0% (1) 34.4% (11)
Aldosterone receptor antagonist 70.0% (7) 43.8% (14)
Diastolic heart failure patients (n = 12) (n = 18)
Beta-adrenoreceptor antagonist 66.7% (8) 55.6% (10)
ACE inhibitor 8.3% (1) 16.7% (3)
Angiotensin receptor blockers 100% (12) 72.2% (13)*
Thiazide diuretic 75.0% (9) 72.2% (13)
Loop diuretic 16.7% (2) 5.6% (1)
Digitalis 25.0% (3) 5.6% (1)
Oral nitrate 25.0% (3) 27.8% (5)
Aldosterone receptor antagonist 83.3% (10) 44.4% (8)
*p < 0.05 compared to microalbuminuria
Table 4. Logistic regression model for microalbuminuria in heart-failure patients.
Variable b Odds ratio P value (Wald test) 95% CI
Diabetes (yes/no) 0.77 2.16 0.20 0.67–6.9
Ejection fraction (%) –0.015 0.98 0.39 0.95–1.02
Volume overload by BIVA (yes/no) 1.45 4.28 0.02 1.28–14.37
Constant –1.37
BIVA — body impedance vector analysis; CI — confidence interval
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of microalbuminuria as a prognostic risk marker,
considering that in our cases it was associated
with higher levels of pulmonary pressure, lesser
serum albumin and more volume overload — all
of them, known markers for worse prognosis.
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